Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Sheridan, Steven D ^a,b   Theriault, Kraig M ^a   Reis, Surya A ^a,b   Zhou, Fen ^a,b   Madison, Jon M ^a,b   Daheron, Laurence ^c,d   Loring, Jeanne F ^e   Haggarty, Stephen J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN REX1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CLONE; CHILD; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FIBROBLAST; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENOME SIZE; GLIA; HUMAN; HUMAN CELL; MALE; NERVE CELL; NERVE CELL DIFFERENTIATION; NUCLEAR REPROGRAMMING; PATHOPHYSIOLOGY; PHENOTYPE; PLURIPOTENT STEM CELL; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; STEM CELL EXPANSION; SYNAPTOGENESIS; TRINUCLEOTIDE REPEAT; BIOLOGICAL MODEL; CASE CONTROL STUDY; CELL CULTURE; CELL DIFFERENTIATION; DONOR; GENETIC EPIGENESIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MIDDLE AGED; MOSAICISM; MUTATION; NERVOUS SYSTEM; NEWBORN; PATHOLOGY;

ADULT; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROBLASTS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOSAICISM; MUTATION; NERVOUS SYSTEM; NEURONS; NUCLEAR REPROGRAMMING; RNA, MESSENGER; TISSUE DONORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 80053948646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026203     Document Type: Article

References (44)

1. Geschwind DH, (2009) Advances in autism. Annu Rev Med 60: 367-380.
2. Rubin LL, (2008) Stem cells and drug discovery: the beginning of a new era? Cell 132: 549-552.
3. Martin JP, Bell J, (1943) A Pedigree of Mental Defect Showing Sex-Linkage. J Neurol Psychiatry 6: 154-157.
4. Crawford DC, Acuna JM, Sherman SL, (2001) FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 3: 359-371.
5. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, et al. (2009) Advances in the treatment of fragile X syndrome. Pediatrics 123: 378-390.
6. Penagarikano O, Mulle JG, Warren ST, (2007) The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet 8: 109-129.
7. Ashley CT Jr, Wilkinson KD, Reines D, Warren ST, (1993) FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262: 563-566.
8. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G, (1993) The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74: 291-298.
9. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ, (2004) Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 24: 2648-2655.
10. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, et al. (1991) Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252: 1097-1102.
11. Kumari D, Usdin K, (2010) The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome. Hum Mol Genet 19: 4634-4642.
12. Kumari D, Usdin K, (2009) Chromatin remodeling in the noncoding repeat expansion diseases. J Biol Chem 284: 7413-7417.
13. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, et al. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3: 64ra61.
14. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427.
15. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, et al. (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23: 628-633.
16. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
17. Abraham S, Sheridan SD, Laurent LC, Albert K, Stubban C, et al. (2010) Propagation of human embryonic and induced pluripotent stem cells in an indirect co-culture system. Biochem Biophys Res Commun 393: 211-216.
18. Sheridan SD, Gil S, Wilgo M, Pitt A, (2008) Microporous membrane growth substrates for embryonic stem cell culture and differentiation. Methods Cell Biol 86: 29-57.
19. Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, et al. (2007) Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1: 568-577.
20. Meisner LF, Johnson JA, (2008) Protocols for cytogenetic studies of human embryonic stem cells. Methods 45: 133-141.
21. Maddalena A, Richards CS, McGinniss MJ, Brothman A, Desnick RJ, et al. (2001) Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genetics in medicine: official journal of the American College of Medical Genetics 3: 200-205.
22. Tost J, Dunker J, Gut IG, (2003) Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 35: 152-156.
23. Brakensiek K, Wingen LU, Langer F, Kreipe H, Lehmann U, (2007) Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem 53: 17-23.
24. Nolin SL, Glicksman A, Houck GE Jr, Brown WT, Dobkin CS, (1994) Mosaicism in fragile X affected males. Am J Med Genet 51: 509-512.
25. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, et al. (1992) DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1: 397-400.
26. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, et al. (2000) Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 66: 6-15.
27. Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, et al. (1995) Translational suppression by trinucleotide repeat expansion at FMR1. Science 268: 731-734.
28. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
29. Maherali N, Hochedlinger K, (2008) Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3: 595-605.
30. Itskovitz-Eldor J, Schuldiner M, Karsenti D, Eden A, Yanuka O, et al. (2000) Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol Med 6: 88-95.
31. Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, et al. (2005) Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci U S A 102: 17834-17839.
32. Bhattacharyya A, McMillan E, Wallace K, Tubon TC Jr, Capowski EE, et al. (2008) Normal Neurogenesis but Abnormal Gene Expression in Human Fragile X Cortical Progenitor Cells. Stem Cells Dev 17: 107-117.
33. Walker FO, (2007) Huntington's disease. Lancet 369: 218-228.
34. Montermini L, Rodius F, Pianese L, Molto MD, Cossee M, et al. (1995) The Friedreich ataxia critical region spans a 150-kb interval on chromosome 9q13. American journal of human genetics 57: 1061-1067.
35. Bontekoe CJ, Bakker CE, Nieuwenhuizen IM, van der Linde H, Lans H, et al. (2001) Instability of a (CGG)98 repeat in the Fmr1 promoter. Hum Mol Genet 10: 1693-1699.
36. Bontekoe CJ, de Graaff E, Nieuwenhuizen IM, Willemsen R, Oostra BA, (1997) FMR1 premutation allele (CGG)81 is stable in mice. Eur J Hum Genet 5: 293-298.
37. Godde JS, Kass SU, Hirst MC, Wolffe AP, (1996) Nucleosome assembly on methylated CGG triplet repeats in the fragile X mental retardation gene 1 promoter. J Biol Chem 271: 24325-24328.
38. Datta S, Alam MP, Majumdar SS, Mehta AK, Maiti S, et al. (2011) Nucleosomal occupancy and CGG repeat expansion: a comparative analysis of triplet repeat region from mouse and human fragile X mental retardation gene 1. Chromosome Res 19: 445-455.
39. Wohrle D, Salat U, Hameister H, Vogel W, Steinbach P, (2001) Demethylation, reactivation, and destabilization of human fragile X full-mutation alleles in mouse embryocarcinoma cells. Am J Hum Genet 69: 504-515.
40. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N, (2010) Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6: 407-411.
41. Ku S, Soragni E, Campau E, Thomas EA, Altun G, et al. (2010) Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 7: 631-637.
42. Braun K, Segal M, (2000) FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb Cortex 10: 1045-1052.
43. Luo Y, Shan G, Guo W, Smrt RD, Johnson EB, et al. (2010) Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 6: e1000898.
44. Castren M, (2006) Differentiation of neuronal cells in fragile X syndrome. Cell Cycle 5: 1528-1530.